Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.

Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quirós Fernández S, Lau A, Richards FM, Jodrell DI.

Mol Cancer Ther. 2018 Jun 11. doi: 10.1158/1535-7163.MCT-18-0010. [Epub ahead of print]

PMID:
29891488
2.

Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

Koh SB, Wallez Y, Dunlop CR, Bernaldo de Quirós Fernández S, Bapiro TE, Richards FM, Jodrell DI.

Cancer Res. 2018 Jun 1;78(11):3054-3066. doi: 10.1158/0008-5472.CAN-17-3932. Epub 2018 May 7.

PMID:
29735549
3.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

4.

Understanding Hematological Toxicities Using Mathematical Modeling.

Fornari C, O'Connor LO, Yates JWT, Cheung SYA, Jodrell DI, Mettetal JT, Collins TA.

Clin Pharmacol Ther. 2018 Mar 31. doi: 10.1002/cpt.1080. [Epub ahead of print] Review.

PMID:
29604045
5.

Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.

Connell CM, Raby SEM, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.

Oncologist. 2018 Jan;23(1):116-117. doi: 10.1634/theoncologist.2017-0226. Epub 2017 Oct 11.

6.

New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.

Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ, Shepherd S, White J, Mark PB, Lynch AG, Jodrell DI, Tavaré S, Earl H.

J Clin Oncol. 2017 Aug 20;35(24):2798-2805. doi: 10.1200/JCO.2017.72.7578. Epub 2017 Jul 7.

7.

Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy.

Jackson RC, Di Veroli GY, Koh SB, Goldlust I, Richards FM, Jodrell DI.

PLoS Comput Biol. 2017 May 3;13(5):e1005529. doi: 10.1371/journal.pcbi.1005529. eCollection 2017 May.

8.

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes.

Connell CM, Raby S, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.

Ann Oncol. 2017 Jul 1;28(7):1678-1679. doi: 10.1093/annonc/mdx181. No abstract available.

9.

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.

Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Löhr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A.

Gut. 2018 Mar;67(3):497-507. doi: 10.1136/gutjnl-2016-311954. Epub 2017 Jan 10.

10.

A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level.

Koh SB, Mascalchi P, Rodriguez E, Lin Y, Jodrell DI, Richards FM, Lyons SK.

J Cell Sci. 2017 Jan 15;130(2):512-520. doi: 10.1242/jcs.195164. Epub 2016 Nov 25.

11.

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.

Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT.

Cell Metab. 2016 Nov 8;24(5):672-684. doi: 10.1016/j.cmet.2016.10.010.

12.

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, Bardeesy N, Hall MN, Quattrochi BJ, Klimstra DS, Barry ST, Sansom OJ, Lewis BC, Morton JP.

Cancer Res. 2016 Dec 1;76(23):6911-6923. Epub 2016 Oct 6.

13.
14.

Combenefit: an interactive platform for the analysis and visualization of drug combinations.

Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, Jodrell DI.

Bioinformatics. 2016 Sep 15;32(18):2866-8. doi: 10.1093/bioinformatics/btw230. Epub 2016 Apr 25.

15.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough S, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O'Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CH.

Clin Cancer Res. 2016 Oct 1;22(19):4827-4836. doi: 10.1158/1078-0432.CCR-15-2507. Epub 2016 Apr 18.

16.

GEMMs as preclinical models for testing pancreatic cancer therapies.

Gopinathan A, Morton JP, Jodrell DI, Sansom OJ.

Dis Model Mech. 2015 Oct 1;8(10):1185-200. doi: 10.1242/dmm.021055. Review.

17.

An automated fitting procedure and software for dose-response curves with multiphasic features.

Di Veroli GY, Fornari C, Goldlust I, Mills G, Koh SB, Bramhall JL, Richards FM, Jodrell DI.

Sci Rep. 2015 Oct 1;5:14701. doi: 10.1038/srep14701.

18.

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

Koh SB, Courtin A, Boyce RJ, Boyle RG, Richards FM, Jodrell DI.

Cancer Res. 2015 Sep 1;75(17):3583-95. doi: 10.1158/0008-5472.CAN-14-3347. Epub 2015 Jul 3.

19.

The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data.

Gill AB, Anandappa G, Patterson AJ, Priest AN, Graves MJ, Janowitz T, Jodrell DI, Eisen T, Lomas DJ.

Magn Reson Imaging. 2015 Feb;33(2):246-51. doi: 10.1016/j.mri.2014.10.010. Epub 2014 Nov 7.

20.

The EGFR demonstrates linear signal transmission.

Oyarzún DA, Bramhall JL, López-Caamal F, Richards FM, Jodrell DI, Krippendorff BF.

Integr Biol (Camb). 2014 Aug;6(8):736-42. doi: 10.1039/c4ib00062e.

PMID:
24934872
21.

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

Bapiro TE, Frese KK, Courtin A, Bramhall JL, Madhu B, Cook N, Neesse A, Griffiths JR, Tuveson DA, Jodrell DI, Richards FM.

Br J Cancer. 2014 Jul 15;111(2):318-25. doi: 10.1038/bjc.2014.288. Epub 2014 May 29.

22.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. doi: 10.1073/pnas.1320318110. Epub 2013 Nov 25.

23.

Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes.

Watts CA, Richards FM, Bender A, Bond PJ, Korb O, Kern O, Riddick M, Owen P, Myers RM, Raff J, Gergely F, Jodrell DI, Ley SV.

Chem Biol. 2013 Nov 21;20(11):1399-410. doi: 10.1016/j.chembiol.2013.09.012. Epub 2013 Oct 24.

24.

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.

Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA.

Gut. 2014 Jun;63(6):974-83. doi: 10.1136/gutjnl-2013-305559. Epub 2013 Sep 25.

25.

Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.

Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI.

PLoS One. 2013 Jun 28;8(6):e67330. doi: 10.1371/journal.pone.0067330. Print 2013.

26.

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.

Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30. doi: 10.1073/pnas.1300415110. Epub 2013 Jul 8.

27.

Adaptive designs for dual-agent phase I dose-escalation studies.

Harrington JA, Wheeler GM, Sweeting MJ, Mander AP, Jodrell DI.

Nat Rev Clin Oncol. 2013 May;10(5):277-88. doi: 10.1038/nrclinonc.2013.35. Epub 2013 Mar 19. Review.

PMID:
23507740
28.

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.

Lin Y, Richards FM, Krippendorff BF, Bramhall JL, Harrington JA, Bapiro TE, Robertson A, Zheleva D, Jodrell DI.

Br J Cancer. 2012 Nov 6;107(10):1692-701. doi: 10.1038/bjc.2012.450. Epub 2012 Oct 4.

29.

Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.

Richards FM, Tape CJ, Jodrell DI, Murphy G.

PLoS One. 2012;7(7):e40597. doi: 10.1371/journal.pone.0040597. Epub 2012 Jul 11.

30.

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA.

Cancer Discov. 2012 Mar;2(3):260-269. doi: 10.1158/2159-8290.CD-11-0242. Epub 2012 Feb 28.

31.

Predictive in vivo animal models and translation to clinical trials.

Cook N, Jodrell DI, Tuveson DA.

Drug Discov Today. 2012 Mar;17(5-6):253-60. Review.

PMID:
22493784
32.

Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.

Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, Jamieson NV, de Sauvage FJ, Tuveson DA, Carroll NR.

Pancreatology. 2012 Jan-Feb;12(1):8-15. doi: 10.1016/j.pan.2011.12.009. Epub 2011 Dec 31.

PMID:
22487467
33.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA.

Gut. 2013 Jan;62(1):112-20. doi: 10.1136/gutjnl-2012-302529. Epub 2012 Mar 30.

34.

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.

Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T, Howat WJ, Jodrell DI, Tuveson DA.

J Exp Med. 2012 Mar 12;209(3):437-44. doi: 10.1084/jem.20111923. Epub 2012 Feb 20.

35.

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.

Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, Acton G, Erlandsson F, Spicer JF.

Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. doi: 10.1158/1078-0432.CCR-10-2490. Epub 2011 Mar 29.

36.

A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1243-53. doi: 10.1007/s00280-011-1613-0. Epub 2011 Mar 23.

37.

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J.

Clin Cancer Res. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. Epub 2010 Aug 30.

38.

Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters.

Kaliszczak M, Antonow D, Patel KI, Howard P, Jodrell DI, Thurston DE, Guichard SM.

AAPS J. 2010 Dec;12(4):617-27. doi: 10.1208/s12248-010-9225-x. Epub 2010 Aug 12.

39.

Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents.

Antonow D, Kaliszczak M, Kang GD, Coffils M, Tiberghien AC, Cooper N, Barata T, Heidelberger S, James CH, Zloh M, Jenkins TC, Reszka AP, Neidle S, Guichard SM, Jodrell DI, Hartley JA, Howard PW, Thurston DE.

J Med Chem. 2010 Apr 8;53(7):2927-41. doi: 10.1021/jm901722v.

PMID:
20218628
40.

How many cisplatin administration protocols does your department use?

Greystoke AP, Jodrell DI, Cheung M, Rivans I, Mackean MJ.

Eur J Cancer Care (Engl). 2010 Jan 1;19(1):80-90. doi: 10.1111/j.1365-2354.2007.00908.x. Epub 2009 Aug 25. Review.

PMID:
19708939
41.

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.

Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF.

Ann Oncol. 2008 Jul;19(7):1340-6. doi: 10.1093/annonc/mdn054. Epub 2008 Mar 5.

PMID:
18325912
42.

Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies.

Patel K, Guichard SM, Jodrell DI.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 15;863(1):19-25. doi: 10.1016/j.jchromb.2007.12.014. Epub 2007 Dec 28.

PMID:
18221921
43.

Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.

Guichard SM, Macpherson JS, Mayer I, Reid E, Muir M, Dodds M, Alexander S, Jodrell DI.

Eur J Cancer. 2008 Jan;44(2):310-7.

PMID:
18077151
44.

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH; EORTC-PAMM-NDDG.

Clin Pharmacokinet. 2007;46(12):1051-68.

PMID:
18027989
45.

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Féty R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH.

Clin Cancer Res. 2007 Nov 1;13(21):6410-8.

46.

ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136.

Aird RE, Thomson M, Macpherson JS, Thurston DE, Jodrell DI, Guichard SM.

Pharmacogenomics J. 2008 Aug;8(4):289-96. Epub 2007 Jun 12.

PMID:
17563765
47.

Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model.

Guichard SM, Hua ML, Kang P, Macpherson JS, Jodrell DI.

Cancer Chemother Pharmacol. 2007 Oct;60(5):651-60. Epub 2007 Feb 2.

PMID:
17273826
48.

Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.

Habtemariam A, Melchart M, Fernandez R, Parsons S, Oswald ID, Parkin A, Fabbiani FP, Davidson JE, Dawson A, Aird RE, Jodrell DI, Sadler PJ.

J Med Chem. 2006 Nov 16;49(23):6858-68.

PMID:
17154516
49.

Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer.

Stark LA, Reid K, Sansom OJ, Din FV, Guichard S, Mayer I, Jodrell DI, Clarke AR, Dunlop MG.

Carcinogenesis. 2007 May;28(5):968-76. Epub 2006 Nov 28.

PMID:
17132819
50.

Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling.

Arnould S, Spanswick VJ, Macpherson JS, Hartley JA, Thurston DE, Jodrell DI, Guichard SM.

Mol Cancer Ther. 2006 Jun;5(6):1602-9.

Supplemental Content

Loading ...
Support Center